Jay Carter, Executive VP, Director of Business Development at AbelsonTaylor and Med Ad News’ 2022 Industry Person of the Year, shares some thoughts about his mentors and career path.

When you have a brand with as much promise as Farxiga, you need someone at the helm with the drive and vision to help it reach its full potential. And that person is senior director of marketing for Farxiga, Allison Garrity. When Garrity joined the Farxiga team, the established AstraZeneca brand already had a strong legacy in type 2 diabetes (T2D), but momentum had stalled, teams needed to be rebuilt, and – the biggest challenge of all – Farxiga had to revolutionize care again, this time with indications in heart failure (HF) and chronic kidney disease (CKD).

Sander Flaum

Looking past COVID, the medical world is in turmoil. It’s hard enough for us in manufacturing and marketing to keep up with innovative technologies. Patients and caregivers have it especially tough since they are on the brunt end of disruptive innovations. Every day, patients face a ceaseless onslaught of sort of truths, half-truths, and flat-out lies about their healthcare, and HCPs no sooner graduate from med school than they discover much of their training is obsolete. Flaum Navigators Principal Sander A. Flaum explores how we can engage patients and physicians in the “Next Big Thing.”

Ogilvy Health hired industry strategist Liz Kane to lead the agency’s Insights, Brand and Medical Strategy offerings. In a Q&A with Med Ad News magazine, Kane shared insights from what she brings to the agency from her 20-year career, including as head of brand strategy at Havas Life, where she led efforts for Pfizer and Amgen, and global consumer advertising stints at Saatchi & Saatchi and Leo Burnett.

Humira could generate more than $20 billion in sales for AbbVie during 2021 while Merck’s Keytruda is on track to become only the second prescription medicine ever to exceed $16 billion in annual sales.

With more than half of the U.S. population fully vaccinated and mask mandates being lifted throughout the country, America looks to resume “normal life” before the pandemic took over. 

Last year challenged biotech and pharma companies to explore what is possible. When several companies can develop COVID-19 vaccines at a record pace, it proves that the industry is capable of massive feats.

Galectin Therapeutics is one of the only biotech companies with an active Phase IIb/III clinical trial for NASH cirrhosis. Galectin recently launched a site dedicated to its study, NAVIGATE: https://navigatenash.com/. Also, the Journal for ImmunoTherapy of Cancer recently published Phase I clinical research showing belapectin, Galectin Therapeutics’ galectin-3 inhibitor, enhances tumor response in combination with anti-PD-1 therapy. Med Ad News discussed these and other topics with Dr. Pol Boudes, CMO of Galectin. 

CEO Usama Malik is leading an exciting period of growth for Fore Biotherapeutics as the company evolves as a leader in precision oncology with its unique business model and ability to deliver the right therapies to currently underserved patients.

Karmen Trzupek, MS, CGC, Director, Rare Disease Genetics and Clinical Trial Services at InformedDNA, talked to Med Ad News about an array of topics including the impact COVID-19 has had on clinical trials throughout the industry.